(Reuters) -The U.S. Food and Drug Administration announced Tuesday that it will allow release of approximately 300,000 cans EleCare infant formula containing amino acids. Abbott Laboratories (NYSE:).

This formula was produced previously at Abbott Nutrition’s Sturgis facility in Michigan. According to the regulator, it would be available for “individuals who urgently require life-sustaining supplies.” This will happen on a case by case basis.

In February, Abbott recalled Similac baby formulas and shut down its Sturgis production plant. This caused one of the most severe infant formula shortages for American families in recent times.

Four infants were infected with bacteria by the biggest U.S. powder baby formula supplier. The facility was closed down. The shortage was exacerbated by the closure of multiple powder baby formula manufacturers. It all started with supply-chain problems related to coronavirus pandemic.

FDA informed U.K. Kendal Nutricare it has given notice that they are exercising their enforcement discretion in regards to certain infant formulas under Kendamil.

According to regulators, the U.K.-based firm expects approximately 2,000,000 cans to arrive on U.S. shelves in June.

According to FDA, “Kendal Nutricare is currently stocking over 40,000 cans for immediate dispatch and U.S. Department of Health and Human Services have initiated discussions to assess options to get the products to the U.S. in a timely manner.”